Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was upgraded by analysts at Wedbush from a “neutral” rating to an “outperform” rating in a research note issued to investors on Thursday, The Fly reports.

Several other analysts have also weighed in on the company. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 30th. Cowen and Company reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research note on Thursday, June 29th. ValuEngine raised Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, BidaskClub raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. Ultragenyx Pharmaceutical has an average rating of “Hold” and a consensus price target of $74.00.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 49.79 on Thursday. The company’s market capitalization is $2.11 billion. Ultragenyx Pharmaceutical has a one year low of $49.56 and a one year high of $91.35. The firm’s 50-day moving average price is $58.78 and its 200 day moving average price is $64.17.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same period last year, the business earned ($1.46) earnings per share. Analysts anticipate that Ultragenyx Pharmaceutical will post ($7.21) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/14/ultragenyx-pharmaceutical-inc-rare-stock-rating-upgraded-by-wedbush.html.

In related news, CEO Emil D. Kakkis acquired 7,500 shares of the stock in a transaction dated Monday, August 28th. The stock was bought at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the transaction, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at $22,613,483.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.20% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Sei Investments Co. bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $125,000. Pacer Advisors Inc. raised its position in shares of Ultragenyx Pharmaceutical by 22.6% during the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 560 shares during the last quarter. Strs Ohio raised its position in shares of Ultragenyx Pharmaceutical by 10.7% during the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 300 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Ultragenyx Pharmaceutical by 3.7% during the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 115 shares during the last quarter. Finally, Tocqueville Asset Management L.P. raised its position in shares of Ultragenyx Pharmaceutical by 8.0% during the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 250 shares during the last quarter. Institutional investors own 96.18% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

The Fly

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.